Bukwang Pharmaceutical Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yoo Hui-Won

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	18.1yrs

Actualizaciones recientes de la dirección

Recent updates

Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?

May 22

Investors In Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Should Consider This, First

Apr 03

Does It Make Sense To Buy Bukwang Pharmaceutical Co., Ltd. (KRX:003000) For Its Yield?

Dec 19

Did You Miss Bukwang Pharmaceutical's (KRX:003000) 90% Share Price Gain?

Nov 23

CEO

Yoo Hui-Won (60 yo)

no data

Permanencia

Ms. Yoo Hui-Won serves as Representative Director of Bukwang Pharmaceutical Co., Ltd. and served as its Chief Executive Officer and Managing Director. Ms. Yoo graduated in Pharmacy from Ewha Womans Univers...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yoo Hui-Won	Representative Director	no data	sin datos	sin datos
Sung-Gu Lee	President & Director	no data	sin datos	sin datos
Won-Tae Park	Managing Director and Director	18.1yrs	sin datos	sin datos
Sang-Hoon Kim	Senior Managing Director	no data	sin datos	sin datos
Dong-Yeon Kim	Chairperson	18.1yrs	sin datos	10.3% ₩ 39.9b
Chang-Soo Jung	Vice Chairman	18.1yrs	sin datos	sin datos
Sam-Moon Cho	Independent Outside Director	no data	sin datos	sin datos
Choon-Taek Yim	Independent Outside Director	no data	sin datos	sin datos
Young-Ho Song	Independent Outside Director	no data	sin datos	sin datos

18.1yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de A003000 son experimentados ( 17.9 años antigüedad media).

Bukwang Pharmaceutical Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Less than half of directors are independent

Bukwang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021

Recent updates

Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?

H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.

H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.

Full year 2023 earnings released: ₩458 loss per share (vs ₩36.00 loss in FY 2022)

Second quarter 2023 earnings released: EPS: ₩7.00 (vs ₩6.00 loss in 2Q 2022)

Full year 2022 earnings released: ₩36.00 loss per share (vs ₩13.00 loss in FY 2021)

Upcoming dividend of ₩100.00 per share

Less than half of directors are independent

Bukwang Pharmaceutical Co., Ltd.(KOSE:A003000) dropped from KOSPI 200 Index

Less than half of directors are independent

Upcoming dividend of ₩90.91 per share

First quarter 2021 earnings released: ₩52.00 loss per share (vs ₩15.00 loss in 1Q 2020)

Investors In Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Should Consider This, First

Full year 2020 earnings released: ₩115 loss per share (vs ₩114 loss in FY 2019)

Did Bukwang Pharmaceutical's (KRX:003000) Share Price Deserve to Gain 71%?

Bukwang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021

New 90-day low: ₩21,050

Is Bukwang Pharmaceutical (KRX:003000) A Risky Investment?

How Much Of Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Do Insiders Own?

Does It Make Sense To Buy Bukwang Pharmaceutical Co., Ltd. (KRX:003000) For Its Yield?

New 90-day high: ₩32,350

Did You Miss Bukwang Pharmaceutical's (KRX:003000) 90% Share Price Gain?

New 90-day low: ₩23,000

New 90-day low: ₩26,700

New 90-day low: ₩32,850

New 90-day high - ₩41,550

CEO

Permanencia

Miembros de la Junta

Permanencia media

Promedio de edad